Caris Life Sciences, Inc. (NASDAQ: CAI)

Sector: Healthcare Industry: Biotechnology CIK: 0002019410
Market Cap 780.64 Mn
P/B 1.63
P/E -2.06
P/S 1.89
ROIC (Qtr) 0.00
Div Yield % 0.00
Rev 1y % (Qtr) 113.38
Total Debt (Qtr) 376.46 Mn
Debt/Equity (Qtr) 0.79

About

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 754.74M provide 4602.07x coverage of short-term debt 164000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 965.23M provides 2.56x coverage of total debt 376.46M, indicating robust asset backing and low credit risk.
  • Tangible assets of 965.23M provide robust 16.97x coverage of other current liabilities 56.87M, indicating strong asset backing.
  • Strong cash position of 754.74M provides 13.27x coverage of other current liabilities 56.87M, indicating excellent liquidity.
  • Cash reserves of 754.74M provide solid 17.20x coverage of other non-current liabilities 43.88M, indicating strong liquidity.

Bear case

  • Retained earnings of (2.63B) provide limited buffer against comprehensive income items of 748000, which is -3516.97x, indicating elevated exposure to market risks.
  • Tangible assets of 965.23M provide limited backing for working capital of 768.22M, which is 1.26x, suggesting increased operational risk in market downturns.
  • Other non-current assets of 46.98M provide minimal coverage for long-term debt of 376.30M, which is 0.12x, indicating potential asset-liability mismatch.
  • Current liabilities of 86.03M significantly exceed receivables of 26.70M, which is 3.22x, indicating potential working capital stress.
  • Other current liabilities of 56.87M represent a high 2.13x of receivables 26.70M, suggesting potential short-term liquidity pressure.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,151.25 Bn -1,249.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 485.22 Bn 7,078.40 97.58 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.74 Bn 33.40 10.47 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 82.16 Bn 18.24 5.73 2.71 Bn
5 ARGX Argenx Se 48.85 Bn 32.43 25,472.44 -
6 ALNY Alnylam Pharmaceuticals, Inc. 46.12 Bn 1,058.58 14.37 3.21 Bn
7 BNTC Benitec Biopharma Inc. 42.24 Bn -1,010.00 0.00 0.00 Bn
8 INSM INSMED Inc 28.75 Bn -24.29 64.32 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.00 11.11
EV to Cash from Ops. EV to Cash from Ops. 0.00 26.32
EV to Debt EV to Debt 0.00 688.48
EV to EBIT EV to EBIT 0.00 -10.97
EV to EBITDA EV to EBITDA 0.00 8.32
EV to Free Cash Flow [EV/FCF] EV to Free Cash Flow [EV/FCF] 0.00 25.03
EV to Market Cap EV to Market Cap 0.00 163.46
EV to Revenue EV to Revenue 0.00 148.57
Price to Book Value [P/B] P/B 1.63 20.73
Price to Earnings [P/E] P/E -2.06 -0.34
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.47
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 860.86
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 -26.99
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 0.00 756.75
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 0.00 -53.03
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 0.00 -4.42
EBIT Growth (1y) % EBIT 1y % (Qtr) 0.00 -62.56
EBT Growth (1y) % EBT 1y % (Qtr) 0.00 -19.19
EPS Growth (1y) % EPS 1y % (Qtr) 0.00 -4.07
FCF Growth (1y) % FCF 1y % (Qtr) 0.00 -33.40
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 0.00 264.38
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 8.77 3.81
Current Ratio Curr Ratio (Qtr) 9.93 7.25
Debt to Equity Ratio Debt/Equity (Qtr) 0.79 0.43
Interest Cover Ratio Int Coverage (Qtr) 0.00 860.86
Times Interest Earned Times Interest Earned (Qtr) 0.00 860.86
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 0.00 -17,746.13
EBIT Margin % EBIT Margin % (Qtr) 0.00 -18,101.92
EBT Margin % EBT Margin % (Qtr) 0.00 -18,961.86
Gross Margin % Gross Margin % (Qtr) 0.00 -9.24
Net Profit Margin % Net Margin % (Qtr) 0.00 -18,911.61